Humira: first licensed hidradenitis suppurativa treatment

The licence for Humira (adalimumab) has been extended to include the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults who have had an inadequate response to conventional HS therapy.

HS is a painful, chronic systemic inflammatory disorder, characterised by inflamed nodules, boils and abscesses located particularly around the groin and underarm.

Further information
View Humira drug record 
Summary of Product Characteristics
Manufacturer: AbbVie

"The approval of Humira to treat moderate to severe HS is a major step forward in supporting patients with this distressing and life-changing condition," commented Dr David Fitzgerald, consultant dermatologist at Salford Royal NHS Foundation Trust. "Patients with HS can experience immense pain and the condition often dramatically impacts their psychological wellbeing and quality of life."

The benefits and risks of long-term treatment should be evaluated regularly and if treatment is interrupted Humira may be reintroduced at the maintenance dose of 40mg per week.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.